<DOC>
	<DOCNO>NCT00830297</DOCNO>
	<brief_summary>Treat-to-target trial basal Insulin Post-transplant hyperglycemia ( TIP ) : efficacy safety novel protocol renal transplant recipient receive tacrolimus-based immunosuppression DESCRIPTION : A prospective , randomized safety efficacy study long-acting insulin ( Insulatard® ) therapy post-transplant hyperglycemia renal transplant recipient OBJECTIVES : Primary Objective : To demonstrate superiority long-acting insulin ( Insulatard® ) post-transplant hyperglycemia , comparison conventional treatment , evaluate HbA1c Secondary Objectives : - To assess average post-transplant glucose level renal transplant patient conventional blood-glucose lower therapy period least 14 day transplantation measure capillary blood glucose level four time daily group patient ( fast , lunch , supper , supper ) - To detect number post-transplant patient - without history pre-transplant diabetes - develop least one episode post-transplant hyperglycemia ( &gt; 140 mg/dl supper ) - To detect average number hyperglycemic episode post-transplant patient least one episode post-transplant hyperglycemia without history diabetes - To assess amount ( long-acting ) insulin ( IU ) need order obtain target capillary blood glucose level range 110 mg/dl 120 mg/dl supper post-transplant patient incidence hyperglycemia - To assess safety long-acting insulin control post-transplant hyperglycemia ( especially regard episode hypoglycemia ( glucose-level &lt; 60 mg/dl ) - To assess prevalence post-transplant diabetes , diagnose abnormal oral glucose tolerance day 90 , 180 360 transplantation , group patient treat long-acting insulin , comparison patient receive conventional treatment - To assess morbidity ( hospitalization , infection , subsequent episode surgery , requirement non-immunosuppressive , non- blood glucose lower medication ) group patient long-acting insulin hyperglycemia , comparison patient randomize group receive conventional treatment - To assess renal outcome ( creatinine level , rejection ) group patient foreseen treat long-acting insulin hyperglycemia , comparison patient randomize group receive conventional treatment</brief_summary>
	<brief_title>Treat-to-target Trial Basal Insulin Post-transplant Hyperglycemia</brief_title>
	<detailed_description>DESIGN / PHASE : Prospective , single-center , randomize , parallel group , control , phase II study . STUDY PLANNED DURATION : First patient First visit 1Q 2009 Last patient First visit 4Q 2009 Last patient Last visit 4Q 2010 CENTERS : Department Internal Medicine III , Division Nephrology Dialysis , Medical University Vienna , Austria , Department Surgery , Division Transplantation , Medical University Vienna , Austria PATIENTS / GROUPS : 50 patient 2 group 25 patient per group Randomization ratio 1:1 , stratification Capillary blood glucose measure four time daily : breakfast ( 7:30 ) , lunch ( 12 pm ) , supper ( 5:30 pm ) supper ( 9 pm ) group nurse personnel/academic investigator . In group No.1 ( study arm A ) , patient treat long-acting insulin ( Insulatard ) soon glucose-level supper surpass 140 mg/dl . The normoglycemic goal group 110 120 mg/dl . In group No.2 ( study arm B ) , glucose level record , treatment leave ward , rely conventional morning glucose measurement . For safety , glucose level &gt; 180 mg/dl report , measure take ward record . As available guideline however concern call `` conventional '' blood glucose-lowering therapy renal transplant patient , especially early post-transplant phase , follow suggestion bring attention ward order standardize treatment patient study arm B : 1 . Treatment group initiate fast glucose level surpasses renal glucose threshold , i.e . 180 mg/dl . 2 . As propose life-style modification treatment NODAT1 feasible early post-transplant phase , basis conventional therapy propose sulfonyl urea drug ( i.e . Gliclazide - Diamicron® , 30 mg , three time daily ) . 3 . Short-acting insulin strongly recommend used correction capillary blood glucose level 250 mg/dl . EFFICACY ENDPOINTS : Primary : - HbA1c level Secondary : - capillary blood glucose profile patient treat long-acting insulin control group , evaluate daily measurement - number patient overall number day hyperglycemia &gt; 140 mg/dl ( group ) - number patient overall number day hyperglycemia &gt; 200 mg/dl ( group ) - number patient overall number day hypoglycemia &lt; 60 mg/dl group - number patient abnormal glucose tolerance day 90 , 180 360 transplantation TOLERABILITY / SAFETY ENDPOINTS : - Number incidence symptomatic hypoglycemia , confirm capillary blood glucose level &lt; 60 mg/dl PHARMACOKINETIC / PHARMACODYNAMIC ENDPOINTS : Doses ( long-acting ) insulin STATISTICAL METHODOLOGY : Primary Endpoint : HbA1c ( rel % ) Null alternative hypothesis : H0 Treatment hyperglycemia &gt; 140 mg/dl supper long-acting insulin renal transplant recipient period least 14 day transplantation equal conventional treatment reduce HbA1c ( measure day 90 transplantation ) . H1 : Treatment hyperglycemia &gt; 140 mg/dl supper long-acting insulin renal transplant recipient period least 14 day transplantation superior conventional treatment reduce HbA1c ( measure day 90 transplantation ) . Type-I -II error - power : α=0.05 ß=0.2 Statistical methodology : One-sided t-test HbA1c day 90 transplantation , one-sided t-test number day hyperglycemia &gt; 140 mg/dl supper , comparison capillary blood glucose level ANOVA Sample size calculation : Based two-sided testing expect standard deviation HbA1c 10 % , α=0.05 ß=0.2 , sample size 25 patient per group determine . Main analysis set : Per-protocol ( efficacy ) intention treat ( ITT ) safety Other endpoint : descriptive statistic</detailed_description>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>renal transplantation ( deceased living donor ) eligibility standard immunosuppression center , consist tacrolimus , mycophenolate mofetil mycophenolic acid , dexamethasone/prednisone triple therapy inform consent patient patient type 1 type 2 diabetes allergy longacting insulin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>TIP</keyword>
	<keyword>NODAT</keyword>
	<keyword>hyperglycemia</keyword>
	<keyword>long-acting insulin</keyword>
	<keyword>post-transplant hyperglycemia</keyword>
</DOC>